CRISPR/Cas systems to overcome challenges in developing the next generation of T cells for cancer therapy.
Ontology highlight
ABSTRACT: Genetically engineered immune cells with chimeric antigen receptors (CAR) or modified T cell receptors (TCR) have demonstrated their potential as a potent class of new cancer therapeutic strategy. Despite the clinical success of autologous CD19 CAR T cells in hematological malignancies, allogeneic T cells exhibit many advantages over their autologous counterparts and have recently gathered widespread attention due to the emergence of multiplex genome editing techniques, particularly CRISPR/Cas systems. Furthermore, genetically engineered T cells face a host of major challenges in solid tumors that are not as significant for blood cancers such as T cell targeted delivery, target specificity, proliferation, persistence, and the immunosuppressive tumor microenvironment. We take this opportuni
SUBMITTER: Huang D
PROVIDER: S-EPMC7736063 | biostudies-literature | 2020
REPOSITORIES: biostudies-literature
ACCESS DATA